Top Markets
Coin of the day
Angion Biomedica Corp. Angion Biomedica Corp.

Angion Biomedica Corp.

ANGN
株式のランク #27863
Angion Biomedica Corp. operates as a biopharmaceutical enterprise,... Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions. Its primary investigational compound, ANG-3070, is an orally administered tyrosine kinase receptor inhibitor currently being developed to address fibrotic ailments, particularly those impacting the kidneys and lungs. The company's product pipeline also features ANG-3777, a hepatocyte growth factor mimetic engineered to treat acute organ injuries like delayed graft function, in addition to initiatives for ROCK2 inhibitors targeting fibrotic diseases and a CYP11B2 inhibitor program. Established in 1998, Angion Biomedica Corp. maintains its headquarters in Uniondale, New York.
株価
$1.00
最終同期: 2023-06-01
時価総額
$30.11M
変化(1日)
2.04%
変化(1年)
0.00%
US
取引 Angion Biomedica Corp. (ANGN)

カテゴリー

Angion Biomedica Corp.(ANGN)の株式分割履歴
Angion Biomedica Corp.株(シンボル:ANGN)は合計で0回の株式分割を実施しました。
最新の株式分割はAug 20, 2026に行われました。
Aug 20, 2026より前に購入されたANGN株は、現在0ANGN株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率
1 x2
US
0 -
US
0 -
NL
1 x3
AU
0 -
CH